CG Oncology (NASDAQ:CGON) Stock Gets Price Target Trim from Guggenheim

CG Oncology (NASDAQ:CGON) had its price target lowered by Guggenheim from $90.00 to $89.00 in a report issued on Monday,Benzinga reports. The firm currently has a buy rating on the stock.

Other analysts have also recently issued research reports about the company. Truist Financial boosted their price target on CG Oncology from $82.00 to $85.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Royal Bank Of Canada lowered their price objective on CG Oncology from $81.00 to $79.00 and set an “outperform” rating on the stock in a report on Friday, August 7th. HC Wainwright reissued a “buy” rating and issued a $100.00 price objective on shares of CG Oncology in a research note on Wednesday, July 29th. Wedbush boosted their target price on CG Oncology from $80.00 to $84.00 and gave the stock an “outperform” rating in a report on Friday, November 6th. Finally, Wall Street Zen raised CG Oncology from a “strong sell” rating to a “sell” rating in a research report on Saturday, November 7th. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $88.11.

CG Oncology Trading Down 0.0%

CG Oncology stock opened at $72.61 on Monday. The company has a market capitalization of $6.49 billion, a P/E ratio of -26.31 and a beta of 0.35. The firm’s fifty day simple moving average is $68.13 and its 200-day simple moving average is $66.36. CG Oncology has a 1-year low of $37.01 and a 1-year high of $80.97.

CG Oncology (NASDAQ:CGON) last issued its quarterly earnings data on Friday, November 6th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.19. The firm had revenue of $1.60 million during the quarter, compared to analysts’ expectations of $0.55 million. CG Oncology had a negative net margin of 3,851.09% and a negative return on equity of 24.58%. On average, equities research analysts predict that CG Oncology will post -3.03 earnings per share for the current year.

Insiders Place Their Bets

In other CG Oncology news, Director Leonard E. Post sold 1,000 shares of the company’s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $62.06, for a total transaction of $62,060.00. Following the completion of the sale, the director directly owned 1,000 shares in the company, valued at $62,060. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last three months, insiders have sold 3,000 shares of company stock worth $209,580. 4.80% of the stock is owned by insiders.

Institutional Investors Weigh In On CG Oncology

Several hedge funds and other institutional investors have recently made changes to their positions in CGON. WINTON GROUP Ltd bought a new stake in CG Oncology during the 2nd quarter valued at approximately $718,000. Legal & General Group Plc acquired a new stake in CG Oncology in the 2nd quarter valued at approximately $2,846,000. Jefferies Financial Group Inc. acquired a new stake in CG Oncology in the 2nd quarter valued at approximately $54,705,000. Jupiter Topco LLC acquired a new stake in CG Oncology in the 2nd quarter valued at approximately $1,634,000. Finally, Bank of America Corp DE bought a new position in CG Oncology in the 2nd quarter worth approximately $69,978,000. 26.56% of the stock is owned by institutional investors and hedge funds.

CG Oncology News Summary

Here’s some of the latest news about CGON:

• Positive Sentiment: CG Oncology’s third-quarter loss was narrower than analysts expected, and revenue exceeded estimates. HC Wainwright also maintained a Buy rating and a $100 price target, raising its FY2026 and Q4 2026 earnings forecasts. What CG Oncology’s Third Quarter Earnings Means For Shareholders
• Neutral Sentiment: A short-interest update reported zero shares sold short and a zero-day days-to-cover ratio, despite describing short interest as having increased. The figures do not indicate a meaningful short position.
• Negative Sentiment: Guggenheim cut its price target for CG Oncology, a potentially bearish analyst signal; the available report does not specify the revised target. CG Oncology Stock Price Target Cut by Guggenheim

CG Oncology Company Profile

CG Oncology is a clinical-stage biotechnology company focused on developing treatments for bladder cancer. Based in Irvine, California, the company’s research centers on therapies delivered directly into the bladder. Its lead investigational therapy, cretostimogene grenadenorepvec (formerly CG0070), is an oncolytic immunotherapy being developed for non-muscle-invasive bladder cancer, including disease that has not responded to Bacillus Calmette-Guérin (BCG) treatment. The modified virus is designed to target cancer cells and stimulate an immune response.